| 11.05 0.01 (0.09%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.9 |
1-year : | 15.07 |
| Resists | First : | 11.05 |
Second : | 12.9 |
| Pivot price | 10.77 |
|||
| Supports | First : | 10.71 |
Second : | 10.51 |
| MAs | MA(5) : | 10.78 |
MA(20) : | 10.78 |
| MA(100) : | 11.05 |
MA(250) : | 10.67 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 62.5 |
D(3) : | 48.3 |
| RSI | RSI(14): 59.7 |
|||
| 52-week | High : | 12.48 | Low : | 10.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IRAA ] has closed below upper band by 12.4%. Bollinger Bands are 12.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11 - 11.05 | 11.05 - 11.1 |
| Low: | 10.59 - 10.65 | 10.65 - 10.71 |
| Close: | 10.63 - 10.72 | 10.72 - 10.8 |
Tribe Capital Growth Corp I does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in San Francisco, California.
Fri, 09 Aug 2024
Iris Acquisition announces key proxy statement details - Investing.com
Wed, 07 Aug 2024
Iris Acquisition Corp announces business combination with Liminatus Pharma - Investing.com
Thu, 25 Jul 2024
Iris Acquisition Corp announces key business combination - Investing.com
Sat, 03 Dec 2022
Dec. 2 Quick Takes: Liminatus heads for NASDAQ via SPAC deal - BioCentury
Thu, 01 Dec 2022
Liminatus Pharma enters SPAC merger deal with Iris Acquisition - Pharmaceutical Technology
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Shell Companies
|
|
| Shares Out | 7 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 1 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -38.11 |
| PEG Ratio | 0 |
| Price to Book value | -4.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -28.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|